Concourse Financial Group Securities, Inc. Cyclerion Therapeutics, Inc. Transaction History

Concourse Financial Group Securities, Inc.

$1.64 Billion
Q3 2024

17 transactions

Quarter	Operation	Price Per share
Q1 2023 May 15, 2023	BUY	$0.43 - $0.9 $0 - $0
Q4 2022 Jan 30, 2023	BUY	$0.42 - $18.8 $0 - $0
Q3 2022 Nov 15, 2022	BUY	$0.58 - $18.2 $0 - $0
Q2 2022 Aug 09, 2022	BUY	$0.47 - $1.29 $0 - $0
Q1 2022 May 09, 2022	BUY	$0.96 - $1.78 $0 - $0
Q4 2021 Feb 07, 2022	BUY	$1.56 - $2.99 $0 - $0
Q3 2021 Nov 09, 2021	BUY	$2.73 - $4.13 $0 - $0
Q2 2021 Aug 13, 2021	BUY	$2.18 - $4.29 $0 - $0
Q1 2021 May 13, 2021	BUY	$2.69 - $5.12 $0 - $0
Q4 2020 Feb 02, 2021	BUY	$2.25 - $7.12 $0 - $0
Q3 2020 Nov 13, 2020	BUY	$3.46 - $8.39 $0 - $0
Q2 2020 Aug 13, 2020	BUY	$2.37 - $7.14 $0 - $0
Q1 2020 May 13, 2020	BUY	$2.46 - $5.84 $0 - $0
Q4 2019 Feb 14, 2020	BUY	$1.8 - $13.43 $0 - $0
Q3 2019 Nov 13, 2019	BUY	$8.12 - $14.54 $0 - $0
Q2 2019 Aug 13, 2019	BUY	$9.6 - $22.85 $0 - $0
Q1 2019 May 15, 2019	BUY	$12.5 - $21.03 $0 - $0

Others Institutions Holding CYCN

# of Institutions

Shares Held

293K

Call Options Held

Put Options Held

Trustcore Financial Services, LLC

293K
Shares

$977,434
0.02% of portfolio

View Full List

About Cyclerion Therapeutics, Inc.

Ticker CYCN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,479,800
Market Cap $145M
Description
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of...

More about CYCN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Account